669 related articles for article (PubMed ID: 23800368)
1. Fluid biomarkers in Alzheimer's disease - current concepts.
Rosén C; Hansson O; Blennow K; Zetterberg H
Mol Neurodegener; 2013 Jun; 8():20. PubMed ID: 23800368
[TBL] [Abstract][Full Text] [Related]
2. [Biomarkers in Alzheimer's disease].
García-Ribas G; López-Sendón Moreno JL; García-Caldentey J
Rev Neurol; 2014 Apr; 58(7):308-17. PubMed ID: 24677154
[TBL] [Abstract][Full Text] [Related]
3. CSF and blood Kallikrein-8: a promising early biomarker for Alzheimer's disease.
Teuber-Hanselmann S; Rekowski J; Vogelgsang J; von Arnim C; Reetz K; Stang A; Jöckel KH; Wiltfang J; Esselmann H; Otto M; Tumani H; Herring A; Keyvani K
J Neurol Neurosurg Psychiatry; 2020 Jan; 91(1):40-48. PubMed ID: 31371645
[TBL] [Abstract][Full Text] [Related]
4. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
5. Clinical significance of fluid biomarkers in Alzheimer's Disease.
Lewczuk P; Łukaszewicz-Zając M; Mroczko P; Kornhuber J
Pharmacol Rep; 2020 Jun; 72(3):528-542. PubMed ID: 32385624
[TBL] [Abstract][Full Text] [Related]
6. Visinin-like protein-1: diagnostic and prognostic biomarker in Alzheimer disease.
Tarawneh R; D'Angelo G; Macy E; Xiong C; Carter D; Cairns NJ; Fagan AM; Head D; Mintun MA; Ladenson JH; Lee JM; Morris JC; Holtzman DM
Ann Neurol; 2011 Aug; 70(2):274-85. PubMed ID: 21823155
[TBL] [Abstract][Full Text] [Related]
7. Alzheimer's Disease-Associated Cerebrospinal Fluid (CSF) Biomarkers do not Correlate with CSF Volumes or CSF Production Rate.
Edsbagge M; Andreasson U; Ambarki K; Wikkelsø C; Eklund A; Blennow K; Zetterberg H; Tullberg M
J Alzheimers Dis; 2017; 58(3):821-828. PubMed ID: 28505972
[TBL] [Abstract][Full Text] [Related]
8. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
11. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
12. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
14. Alzheimer's disease--Recent biomarker developments in relation to updated diagnostic criteria.
Höglund K; Fourier A; Perret-Liaudet A; Zetterberg H; Blennow K; Portelius E
Clin Chim Acta; 2015 Sep; 449():3-8. PubMed ID: 25668231
[TBL] [Abstract][Full Text] [Related]
15. Cerebrospinal fluid levels of total-tau, phospho-tau and A beta 42 predicts development of Alzheimer's disease in patients with mild cognitive impairment.
Andreasen N; Vanmechelen E; Vanderstichele H; Davidsson P; Blennow K
Acta Neurol Scand Suppl; 2003; 179():47-51. PubMed ID: 12603251
[TBL] [Abstract][Full Text] [Related]
16. Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.
Pérez-Grijalba V; Romero J; Pesini P; Sarasa L; Monleón I; San-José I; Arbizu J; Martínez-Lage P; Munuera J; Ruiz A; Tárraga L; Boada M; Sarasa M
J Prev Alzheimers Dis; 2019; 6(1):34-41. PubMed ID: 30569084
[TBL] [Abstract][Full Text] [Related]
17. Biomarkers for Alzheimer's disease: current status and prospects for the future.
Blennow K; Zetterberg H
J Intern Med; 2018 Dec; 284(6):643-663. PubMed ID: 30051512
[TBL] [Abstract][Full Text] [Related]
18. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease.
Blennow K; Hampel H; Weiner M; Zetterberg H
Nat Rev Neurol; 2010 Mar; 6(3):131-44. PubMed ID: 20157306
[TBL] [Abstract][Full Text] [Related]
19. Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S; Zetterberg H; Mattsson N; Johansson P; ; Minthon L; Blennow K; Olsson M; Hansson O;
Neurology; 2015 Oct; 85(14):1240-9. PubMed ID: 26354982
[TBL] [Abstract][Full Text] [Related]
20. Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.
Burnham SC; Coloma PM; Li QX; Collins S; Savage G; Laws S; Doecke J; Maruff P; Martins RN; Ames D; Rowe CC; Masters CL; Villemagne VL
J Prev Alzheimers Dis; 2019; 6(4):248-255. PubMed ID: 31686097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
